Search Results - Hinson, Nigel

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Faculty of Prehospital Care, Royal College of Surgeons Edinburgh guidance for medical provision for wilderness medicine

    Faculty of Prehospital Care, Royal College of Surgeons Edinburgh guidance for medical provision for wilderness medicine by Mellor, Adrian, Dodds, Naomi, Joshi, Raj, Hall, John, Dhillon, Sundeep, Hollis, Sarah, Davis, Pete, Hillebrandt, David, Howard, Eva, Wilkes, Matthew, Langdana, Burjor, Lee, David, Hinson, Nigel, Williams, Thomas Harcourt, Rowles, Joe, Pynn, Harvey

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial

    A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial by Othman, Jad, Wilhelm-Benartzi, Charlotte, Dillon, Richard, Knapper, Steve, Freeman, Sylvie D., Batten, Leona M., Canham, Joanna, Hinson, Emily L., Wych, Julie, Betteridge, Sophie, Villiers, William, Kleeman, Michelle, Gilkes, Amanda, Potter, Nicola, Overgaard, Ulrik Malthe, Mehta, Priyanka, Kottaridis, Panagiotis, Cavenagh, Jamie, Hemmaway, Claire, Arnold, Claire, Dennis, Mike, Russell, Nigel H.

    Published in Blood advances
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial

    FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival... by Russell, Nigel H., Wilhelm-Benartzi, Charlotte, Knapper, Steve, Batten, Leona M, Canham, Joanna, Hinson, Emily L, Overgaard, Ulrik Malthe, Gilkes, Amanda, Othman, Jad, Potter, Nicola, Dillon, Richard, Mehta, Priyanka, Kottaridis, Panagiotis, Cavenagh, Jamie, Hemmaway, Claire, Arnold, Claire, Freeman, Sylvie D, Dennis, Mike

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial

    Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 T... by Othman, Jad, Dillon, Richard, Wilhelm-Benartzi, Charlotte, Knapper, Steve, Batten, Leona M, Canham, Joanna, Hinson, Emily L, Villiers, William, Kleeman, Michelle, Gilkes, Amanda, Potter, Nicola, Overgaard, Ulrik Malthe, Mehta, Priyanka, Kottaridis, Panos, Cavenagh, Jamie, Hemmaway, Claire, Arnold, Claire, Dennis, Mike, Russell, Nigel H.

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    P484: GEMTUZUMAB‐BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. UPDATED TOXICITY AND INTERIM SURVIVAL ANALYSIS FROM THE NCRI AML19V2 “MIDOTARG” PILOT TRIAL

    P484: GEMTUZUMAB‐BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. UPDATED TOXICITY AND INTERIM SURVIVAL ANALYSIS FROM THE NCRI AML19V2 “MIDOTARG” PILOT... by Russell, Nigel, Cumming, Oliver, Othman, Jad, Dillon, Richard, Potter, Nicola, Wilhelm‐Benartzi, Charlotte, Jovanovic, Jelena, Gilkes, Amanda, Batten, Leona, Canham, Joanna, Laura Hinson, Emily, Kottaridis, Panagiotis, Cavenagh, Jamie, Arnold, Claire, Dennis, Mike, Knapper, Steven

    Published in HemaSphere
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    S134: FLAG‐IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL

    S134: FLAG‐IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 T... by Russell, Nigel, Othman, Jad, Dillon, Richard, Potter, Nicola, Wilhelm‐Benartzi, Charlotte, Knapper, Steven, Batten, Leona, Canham, Joanna, Hinson, Emily Laura, Malthe Overgaard, Ulrik, Gilkes, Amanda, Mehta, Priyanka, Kottaridis, Panagiotis, Cavenagh, Jamie, Hemmaway, Claire, Arnold, Claire, Freeman, Sylvie, Dennis, Mike

    Published in HemaSphere
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: